Search...
RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
I'm PortAI, I can summarize articles.
According to TipRanks, Timashev is a 5-star analyst with an average return of 28.0% and a 60.34% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Alkermes, Insmed, and IDEAYA Biosciences. COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $19.67.
According to TipRanks, Timashev is a 5-star analyst with an average return of 28.0% and a 60.34% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Alkermes, Insmed, and IDEAYA Biosciences.
COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $19.67.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments